SG11201504843UA - Non-replicating virus-derived particles and uses thereof - Google Patents

Non-replicating virus-derived particles and uses thereof

Info

Publication number
SG11201504843UA
SG11201504843UA SG11201504843UA SG11201504843UA SG11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA SG 11201504843U A SG11201504843U A SG 11201504843UA
Authority
SG
Singapore
Prior art keywords
derived particles
replicating virus
replicating
virus
particles
Prior art date
Application number
SG11201504843UA
Inventor
David Conrad
Cory Batenchuk
Fabrice Leboeuf
John Cameron Bell
Original Assignee
Ottawa Hospital Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50977496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201504843U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ottawa Hospital Res Inst filed Critical Ottawa Hospital Res Inst
Publication of SG11201504843UA publication Critical patent/SG11201504843UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20263—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11201504843UA 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof SG11201504843UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261740856P 2012-12-21 2012-12-21
US201361835310P 2013-06-14 2013-06-14
PCT/CA2013/051009 WO2014094182A1 (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Publications (1)

Publication Number Publication Date
SG11201504843UA true SG11201504843UA (en) 2015-07-30

Family

ID=50977496

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201504843UA SG11201504843UA (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof
SG10201704903YA SG10201704903YA (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201704903YA SG10201704903YA (en) 2012-12-21 2013-12-20 Non-replicating virus-derived particles and uses thereof

Country Status (18)

Country Link
US (2) US11110138B2 (en)
EP (1) EP2935569B1 (en)
JP (2) JP6612619B2 (en)
KR (1) KR102167497B1 (en)
CN (1) CN105121636A (en)
AU (1) AU2013362761B2 (en)
BR (1) BR112015015045A8 (en)
CA (1) CA2896162C (en)
CL (1) CL2015001738A1 (en)
ES (1) ES2745599T3 (en)
HK (1) HK1210624A1 (en)
IL (1) IL239486B (en)
MX (1) MX2015008155A (en)
MY (1) MY174912A (en)
PH (1) PH12015501442A1 (en)
RU (1) RU2705556C2 (en)
SG (2) SG11201504843UA (en)
WO (1) WO2014094182A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105121636A (en) * 2012-12-21 2015-12-02 渥太华医院研究所 Non-replicating virus-derived particles and uses thereof
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN109985244A (en) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 E3 connection enzyme inhibitor and oncolytic virus are in the application for preparing anti-tumor drug
CN109432098B (en) * 2018-11-20 2021-04-13 天津大学 Application of compound PS-341 in preparation of small RNA virus family enterovirus genus virus inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106619A (en) 1983-12-20 1992-04-21 Diamond Scientific Co. Preparation of inactivated viral vaccines
IL153570A0 (en) 2000-06-26 2003-07-06 Wellstat Biologics Corp Purging of cells using viruses
CN1820078A (en) * 2002-09-09 2006-08-16 田纳西大学研究基金会 Recombinant mutants of rhabdovirus and methods of use thereof
CN100579579C (en) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 Anti-cancer and anti-infectious disease compositions and methods for using same
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
JP4708027B2 (en) * 2002-10-01 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Anti-cancer compositions and anti-infective disease compositions and methods of using them
CA2520279C (en) * 2003-03-27 2012-09-04 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
JP4705026B2 (en) * 2004-03-19 2011-06-22 ジェノミディア株式会社 Vascular endothelial growth promoting gene
US8703467B2 (en) * 2004-05-27 2014-04-22 Baxter International Inc. Inactivation of a pathogen in a sample by a treatment with formalin and UV light
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
US8691212B2 (en) * 2008-09-16 2014-04-08 Genomldea Inc. Therapeutic/prophylactic agent for prostate cancer
AU2010329551B2 (en) 2009-12-10 2016-02-11 Turnstone Limited Partnership Oncolytic rhabdovirus
EP2667893A2 (en) 2011-01-27 2013-12-04 Lentigen Corporation Advanced prime and boost vacinne
CN103403594B (en) * 2011-02-02 2016-11-23 康宁光缆系统有限责任公司 The optical backplane being suitable in equipment rack sets up the joints of optical fibre that cover of dense light valve and the assembly that optics connects
WO2012122649A1 (en) * 2011-03-15 2012-09-20 Ottawa Hospital Research Institute Recombinant orf virus
US9623096B2 (en) * 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof
CN105121636A (en) * 2012-12-21 2015-12-02 渥太华医院研究所 Non-replicating virus-derived particles and uses thereof

Also Published As

Publication number Publication date
IL239486B (en) 2019-08-29
US20210346441A1 (en) 2021-11-11
CN105121636A (en) 2015-12-02
RU2705556C2 (en) 2019-11-07
BR112015015045A8 (en) 2018-01-23
US20150320810A1 (en) 2015-11-12
JP6612619B2 (en) 2019-11-27
RU2015128766A (en) 2017-01-26
US11110138B2 (en) 2021-09-07
ES2745599T3 (en) 2020-03-02
MY174912A (en) 2020-05-21
KR102167497B1 (en) 2020-10-20
SG10201704903YA (en) 2017-07-28
EP2935569A4 (en) 2016-08-03
CA2896162C (en) 2021-10-12
PH12015501442A1 (en) 2015-09-14
EP2935569A1 (en) 2015-10-28
EP2935569B1 (en) 2019-05-01
AU2013362761A1 (en) 2015-07-16
WO2014094182A1 (en) 2014-06-26
KR20150112957A (en) 2015-10-07
HK1210624A1 (en) 2016-04-29
JP2020014467A (en) 2020-01-30
JP2016501538A (en) 2016-01-21
IL239486A0 (en) 2015-07-30
MX2015008155A (en) 2016-02-05
CA2896162A1 (en) 2014-06-26
NZ709439A (en) 2020-09-25
CL2015001738A1 (en) 2015-12-18
AU2013362761B2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
IL256716A (en) Anti-hla-b*27 antibodies and uses thereof
HK1210790A1 (en) Modified factor polypeptides and uses thereof
HK1199023A1 (en) Substituted benzothienylpyrrolotriazines and uses thereof
HRP20190358T1 (en) Anti-asic1 antibodies and uses thereof
HK1200822A1 (en) Substituted dipyridylamines and uses thereof
HK1210913A1 (en) Particles, methods and uses thereof
SG11201500111VA (en) Peptides and uses thereof
HK1210809A1 (en) Beta-hexosyl-transferases and uses thereof
EP2825548A4 (en) Modified kisspeptin peptides and uses thereof
HK1210624A1 (en) Non-replicating virus-derived particles and uses thereof
HK1211042A1 (en) Inflammation-enabling polypeptides and uses thereof
IL237400A0 (en) Rhizobacteria and uses thereof
ZA201504462B (en) TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
GB201217832D0 (en) Fine particles
GB201208372D0 (en) Antibodies and uses thereof